EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of barriers to implementation of precision oncology in patients with rare cancers

Shigemasa Takamizawa iD, Takafumi Koyama iD, Kuniko Sunami iD, Kazuki Sudo iD, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho iD, Yoshitaka Narita, Ken Kato iD, Naoya Yamazaki iD, Yuichiro Ohe iD und 5 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Shigemasa Takamizawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Molecular Targeted Therapy, Rare Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Established treatment options for rare cancers are limited by the small number of patients. The current comprehensive genomic profiling (CGP) testing might not fully exploit opportunities for precision oncology in patients with rare cancers. Therefore, we aimed to explore the factors associated with CGP testing utility in rare cancers and identify barriers to implementing precision oncology. Patients who underwent CGP testing at our institution between September 2019 and June 2021 were enrolled in this retrospective study. Based on their results, the patients received molecularly targeted drugs or immune checkpoint inhibitors. Univariate and multivariate analyses evaluated the association between patient characteristics and the proportion of patients receiving molecularly targeted drugs. Overall, 790 patients underwent CGP testing. Among them, 333 patients with rare cancers were identified, of whom 278 (83.5%) had actionable genomic alterations, 127 (38.1%) had druggable genomic alterations, and 25 (7.5%) received genomically matched therapy. The proportion of patients receiving molecularly targeted drugs was significantly higher among those with treatment options with evidence levels A–D (8.7%) than those without treatment options with evidence levels A–D (2.9%). A potential barrier to CGP testing utility in rare cancers is the limited number of molecularly targeted drugs with clinical evidence. We propose that CGP testing be performed in patients with rare cancers who have treatment options with evidence levels A–D to maximize CGP testing utility in real‐world practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineNeoplasmsMolecular Targeted TherapyRare DiseasesHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overGenomicsYoung AdultMedical OncologyImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

cancerdrug developmentdrug therapymolecularly targeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.
  • Division of Translational Genomics, National Cancer Center-Exploratory Oncology Research and Clinical Trial Center, Tokyo, Japan.
  • Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Hourin Cho, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Kan Yonemori, Noboru Yamamoto

Zitieren

APA

Takamizawa, S., Koyama, T., Sunami, K., Sudo, K., Hirata, M., Kubo, T., Tao, K., Cho, H., Narita, Y., Kato, K., Yamazaki, N., Ohe, Y., Okusaka, T., Matsui, Y., Ogawa, C., Yonemori, K., & Yamamoto, N. (2024). Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer Science. https://doi.org/10.1111/cas.16165

Vancouver

Takamizawa S, Koyama T, Sunami K, Sudo K, Hirata M, Kubo T, et al. Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer Science. 2024. doi:10.1111/cas.16165

BibTeX
@article{Takamizawa2024,
  author = {Takamizawa, Shigemasa and Koyama, Takafumi and Sunami, Kuniko and Sudo, Kazuki and Hirata, Makoto and Kubo, Takashi and Tao, Kayoko and Cho, Hourin and Narita, Yoshitaka and Kato, Ken and Yamazaki, Naoya and Ohe, Yuichiro and Okusaka, Takuji and Matsui, Yoshiyuki and Ogawa, Chitose and Yonemori, Kan and Yamamoto, Noboru},
  title = {Identification of barriers to implementation of precision oncology in patients with rare cancers},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16165}
}
Kostenlos starten →